Nav: Home

BU researchers discover therapeutic target of melanoma

March 25, 2019

(Boston)--Researchers have identified a biomarker and a possible new therapy for melanoma.

Microphthalmia-associated transcription factor (MITF) is a protein that plays a pivotal role in the maintenance of the melanocyte (cells that make melanin) lineage, differentiation of normal and malignant melanocytes and the survival of melanoma cells.

"We have now detected the first useful chemical inhibitor of MITF," said corresponding author Rhoda Alani, MD, the Herbert Mescon Chair of Dermatology at Boston University School of Medicine.

While genetic mutations in human melanomas have been explored extensively over the past decade, the role of epigenetic alterations in melanoma development and progression has been less clearly defined.

The researchers found that inhibition of the epigenetic p300 Histone Acetyltransferase (HAT) enzyme prevents growth of human melanoma cells and cells with increased expression of MITF are most sensitive to this inhibition.

"When human melanoma cell lines were evaluated for growth effects using the chemical inhibitor of p300 HAT, the cell lines that were most sensitive to drug treatment were those that expressed high levels of MITF suggesting that MITF expression levels can predict melanoma sensitivity to such therapies," explained Alani, who also is chief of dermatology at Boston Medical Center.

According to the researchers, this inhibitor may have broad implications for the treatment of pigmented lesions in the skin and could potentially be used topically to treat hyperpigmentation.

They hope this study will provide an incentive to pursue additional epigenetic approaches to cancers, both as direct agents targeting specific cancers as well as adjuvant therapies to improve responses to cancer immunotherapies.
-end-
In addition to Alani, Philip Cole, MD, PhD, professor of medicine and biological chemistry and molecular pharmacology at Harvard University is the other co-corresponding author.

These findings appear in the online journal Cancer Research.

Funding for this study was provided by Grant No R37GM62437 awarded by National Institutes of Health, a CTSA grant UL1TR001079 and FAMRI (Flight Attendant Medical Research Institute). A Jane Coffin Childs Fund postdoctoral fellowship and an ASA Medical Student Grant also provided support.

Editors Note: RMA is a cofounder and shareholder for Acylin Therapeutics Inc. which is developing p300/CBP HAT inhibitors. PAC is a cofounder, shareholder and paid consultant for Acylin Therapeutics Inc. which is developing p300/CBP HAT inhibitors. He is also a paid consultant for Abbvie Inc. which is pursuing the development of p300/CBP HAT inhibitors.

Boston University School of Medicine

Related Melanoma Articles:

Blood test for deadly eye melanoma
A simple blood test could soon become the latest monitoring tool for the early detection of melanoma in the eye.
Analysis of melanoma in US by age groups
This study used registry data to determine annual rates of melanoma in pediatric, adolescent, young adult and adult age groups, and the findings suggest an apparent decrease among adolescent and young adults between 2006 and 2015 but increases in older adults.
Vitamin D dials down the aggression in melanoma cells
Vitamin D influences the behaviour of melanoma cells in the lab by making them less aggressive, Cancer Research UK scientists have found.
B cells linked to immunotherapy for melanoma
Immunotherapy uses our body's own immune system to fight cancer.
Five things to know about melanoma
'Five things to know about ... melanoma' in CMAJ (Canadian Medical Association Journal) provides a brief overview of this malignant skin cancer for physicians and patients.
Describing aspects of melanoma progression
Three related articles and an editorial focus on various aspects of melanoma progression.
Is your melanoma hot enough for immunotherapy?
University of Colorado Cancer Center study presented at AACR 2019 shows that tumors with mutations in genes leading to over-activation of the NF-kB signaling pathway were more than three times as likely to respond to anti-PD1 immunotherapy compared with tumors in which these changes were absent.
BU researchers discover therapeutic target of melanoma
Researchers have identified a biomarker and a possible new therapy for melanoma.
Seawater bacteria provides leads to fight melanoma
Malignant melanoma can be a particularly dangerous form of cancer, and more therapeutic options are needed.
New drug combination could be more effective against melanoma
A new study from MIT suggests that combining kinase inhibitors with experimental drugs known as ribonucleases could lead to better results.
More Melanoma News and Melanoma Current Events

Top Science Podcasts

We have hand picked the top science podcasts of 2019.
Now Playing: TED Radio Hour

In & Out Of Love
We think of love as a mysterious, unknowable force. Something that happens to us. But what if we could control it? This hour, TED speakers on whether we can decide to fall in — and out of — love. Guests include writer Mandy Len Catron, biological anthropologist Helen Fisher, musician Dessa, One Love CEO Katie Hood, and psychologist Guy Winch.
Now Playing: Science for the People

#541 Wayfinding
These days when we want to know where we are or how to get where we want to go, most of us will pull out a smart phone with a built-in GPS and map app. Some of us old timers might still use an old school paper map from time to time. But we didn't always used to lean so heavily on maps and technology, and in some remote places of the world some people still navigate and wayfind their way without the aid of these tools... and in some cases do better without them. This week, host Rachelle Saunders...
Now Playing: Radiolab

Dolly Parton's America: Neon Moss
Today on Radiolab, we're bringing you the fourth episode of Jad's special series, Dolly Parton's America. In this episode, Jad goes back up the mountain to visit Dolly's actual Tennessee mountain home, where she tells stories about her first trips out of the holler. Back on the mountaintop, standing under the rain by the Little Pigeon River, the trip triggers memories of Jad's first visit to his father's childhood home, and opens the gateway to dizzying stories of music and migration. Support Radiolab today at Radiolab.org/donate.